Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chan Y Cheah

Showing results (41-50 of 122) with videos related to

Pageof 13
Sort By:
European Journal of Haematology|May 15, 2013
All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximabChan Y Cheah, Thomas E Lew, Rebecca Lee, et al.
Pathology|March 17, 2023
Myeloid sarcoma: a poorly recognised but important differential diagnosis of epithelioid angiosarcomaDaniel D Wong, Rodas Amanuel, Yee Jia Chua, et al.
Asia-Pacific Journal of Clinical Oncology|April 15, 2020
A consensus statement on the use of biosimilar medicines in hematology in AustraliaGareth P Gregory, Christine Carrington, Chan Y Cheah, et al.
Leukemia & Lymphoma|August 29, 2020
Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma AllianceMatthew Harwood, Georgina Hodges, Xuan Tan, et al.
Clinical Epigenetics|January 28, 2023
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myelomaJake Shortt, Peter Galettis, Chan Y Cheah, et al.
British Journal of Haematology|December 20, 2015
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicityChan Y Cheah, Loretta J Nastoupil, Peter McLaughlin, et al.
British Journal of Haematology|July 7, 2018
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvementDai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Leukemia & Lymphoma|October 18, 2024
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab eraDaniel Fasser, Katharine Lewis, Connull Leslie, et al.
Internal Medicine Journal|April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphomaMichael Dickinson, Nicole O'Leary, Nada Hamad, et al.
Leukemia & Lymphoma|November 24, 2022
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient ProgramStephen P Mulligan, Stephen Opat, Chan Y Cheah, et al.
Pageof 13

Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
European Journal of Haematology|May 15, 2013
All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximabChan Y Cheah, Thomas E Lew, Rebecca Lee, et al.
Pathology|March 17, 2023
Myeloid sarcoma: a poorly recognised but important differential diagnosis of epithelioid angiosarcomaDaniel D Wong, Rodas Amanuel, Yee Jia Chua, et al.
Asia-Pacific Journal of Clinical Oncology|April 15, 2020
A consensus statement on the use of biosimilar medicines in hematology in AustraliaGareth P Gregory, Christine Carrington, Chan Y Cheah, et al.
Leukemia & Lymphoma|August 29, 2020
Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma AllianceMatthew Harwood, Georgina Hodges, Xuan Tan, et al.
Clinical Epigenetics|January 28, 2023
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myelomaJake Shortt, Peter Galettis, Chan Y Cheah, et al.
British Journal of Haematology|December 20, 2015
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicityChan Y Cheah, Loretta J Nastoupil, Peter McLaughlin, et al.
British Journal of Haematology|July 7, 2018
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvementDai Chihara, Yasuhiro Oki, Michelle A Fanale, et al.
Leukemia & Lymphoma|October 18, 2024
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab eraDaniel Fasser, Katharine Lewis, Connull Leslie, et al.
Internal Medicine Journal|April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphomaMichael Dickinson, Nicole O'Leary, Nada Hamad, et al.
Leukemia & Lymphoma|November 24, 2022
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient ProgramStephen P Mulligan, Stephen Opat, Chan Y Cheah, et al.
Pageof 13